+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Encephalopathy Market by Treatment Type, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030- Product Image
Encephalopathy Market by Treatment Type, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Encephalopathy Market by Treatment Type, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015276
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Encephalopathy Market grew from USD 196.85 million in 2024 to USD 209.06 million in 2025. It is expected to continue growing at a CAGR of 6.15%, reaching USD 281.70 million by 2030.

A Strategic Overview of Encephalopathy’s Clinical and Market Dynamics

Encephalopathy represents a complex and multifaceted group of neurological disorders that disrupt brain function through metabolic, toxic, infectious, or structural pathways. As global demographics shift toward an aging population and chronic liver disease continues to rise, the imperative to unravel the nuances of encephalopathy has never been greater. This report begins by mapping the critical drivers shaping patient outcomes, clinical practices, and innovation in treatment modalities.

Readers will gain a clear understanding of how advancements in diagnostic imaging, biomarker discovery, and interdisciplinary care models are redefining the standard of care. The introduction sets the stage for a deep dive into the forces altering the competitive landscape, offering stakeholders a solid foundation for informed strategic planning.

Key Innovations and Systemic Shifts Shaping the Encephalopathy Arena

Recent years have witnessed transformative shifts that are redefining the encephalopathy market. Emerging data on the gut-brain axis have elevated the importance of microbiome-targeted therapies, pushing pharmaceutical innovators to explore next-generation antibiotics and prebiotic formulations. Simultaneously, miniaturization and enhanced automation in extracorporeal blood purification systems are enabling clinicians to deliver more precise detoxification protocols, improving safety and patient comfort.

In surgical domains, advancements in minimally invasive shunt procedures and organ support technologies are gradually reducing perioperative risk. Beyond technology, evolving reimbursement frameworks and value-based care models are incentivizing outcomes-driven approaches, fostering collaborations between device manufacturers, pharmaceutical companies, and care providers. These converging trends are driving a new era of integrated treatment pathways.

Assessing the Impact of New Tariff Policies on Treatment Accessibility

The implementation of revised United States tariffs in 2025 has introduced notable repercussions for technologies and therapies integral to managing encephalopathy. Tariff adjustments on specialized hemodialysis equipment have increased procurement costs for healthcare institutions, prompting decision-makers to reassess budget allocations for extracorporeal support systems. Concurrently, levies imposed on primary active pharmaceutical ingredients have led to incremental price adjustments for core treatments such as lactulose and rifaximin.

Manufacturers have responded by exploring localized production and strategic supply chain realignment to mitigate cost pressures. Meanwhile, service providers are negotiating new contracting models to stabilize pricing and safeguard patient access. This section delves into how stakeholders across manufacturing, distribution, and clinical care are adapting to policy-induced headwinds while maintaining operational resilience and continuity of critical therapeutic services.

Illuminating Market Segmentation to Guide Targeted Strategies

Segmenting the encephalopathy market by treatment type reveals distinctive growth trajectories. Devices encompass blood purification systems, hemodialysis platforms, and liver support devices that are evolving with greater automation and biocompatible materials. In pharmaceuticals, established mainstays such as lactulose and rifaximin are benefiting from formulation enhancements that improve patient adherence and reduce adverse events. Surgical interventions, including liver transplantation and shunt surgeries, continue to progress through refined techniques that lower complication rates and expand eligibility criteria.

When viewed through distribution channels, hospital pharmacies remain the predominant conduit for comprehensive inpatient care, while online pharmacies are gaining traction for chronic medication refill convenience and retail pharmacies sustain a broad community footprint. End users range from specialized clinics offering targeted outpatient protocols to home care settings where remote monitoring and telehealth integration are redefining post-acute management. Hospital networks continue to consolidate their position as centers of excellence, leveraging multidisciplinary teams to deliver cohesive treatment regimens.

Patient age group segmentation sheds light on differential market needs. Adult populations drive demand for standard protocols with an emphasis on outpatient maintenance therapies. Geriatric cohorts require tailored approaches that address comorbidities and polypharmacy, magnifying the need for simplified dosing and minimally invasive interventions. Pediatric cases, though less prevalent, necessitate age-appropriate formulations and specialized surgical expertise, underscoring the importance of dedicated care pathways.

Regional Variations That Define the Global Treatment Ecosystem

Regional dynamics play a pivotal role in shaping encephalopathy care models and investment priorities. In the Americas, integrated healthcare systems and robust reimbursement frameworks are accelerating the adoption of advanced extracorporeal devices, while pharmaceutical access programs are expanding therapeutic reach among underserved populations. The Europe, Middle East & Africa region exhibits heterogeneity in infrastructure, with Western European markets leading in precision diagnostics and emerging Middle Eastern hubs investing heavily in transplant programs. Africa remains challenged by resource constraints yet shows promise through public-private partnerships aimed at capacity building.

The Asia-Pacific landscape is characterized by rapid technological adoption and a substantial patient pool that drives economies of scale. National health initiatives in countries such as Japan and Australia are funding clinical research into novel antibiotics, whereas markets like India and China are focusing on cost-effective manufacturing of generics to enhance regional accessibility. Across all regions, cross-border collaborations and knowledge exchange platforms are fostering a more cohesive global response to the complexities of encephalopathy management.

Competitive Movements Reshaping Leadership in Encephalopathy Care

Leading corporations and innovative newcomers alike are jockeying to establish their foothold in the encephalopathy arena. Major medical device manufacturers are expanding their portfolios through strategic partnerships with biotech firms to integrate point-of-care sensor technologies into liver support systems. Pharmaceutical heavyweights are diversifying pipelines by investing in microbiome science startups to challenge the status quo in bacterial modulation therapies. Concurrently, specialized surgical device developers are securing regulatory approvals for next-generation minimally invasive tools that streamline shunt placement and reduce patient recovery times.

Competitive positioning is further influenced by mergers and acquisitions aimed at creating end-to-end solution providers. Legacy companies are shuttering internal silos to present unified offerings that span diagnostics, treatment delivery, and post-therapy monitoring. Regional players are leveraging their local market insights to adapt global platforms to country-specific requirements, thereby gaining traction among healthcare providers seeking tailored implementation support. This section unpacks the strategies that are setting tomorrow’s market leaders apart.

Strategic Priorities to Drive Market Leadership and Innovation

Industry leaders should seize the moment to accelerate innovation and fortify market positions. First, establishing cross-disciplinary centers of excellence that unite hepatologists, nephrologists, and neurologists can drive holistic care pathways and bolster outcome data that influence payer decisions. Second, engaging in co-development agreements with biotech pioneers focused on microbiome modulation will position organizations at the vanguard of next-generation therapies. Third, investing in modular, scalable manufacturing closer to key markets can preempt supply chain disruptions induced by shifting tariffs and geopolitical volatility.

Moreover, enhancing digital health capabilities through telemedicine platforms and remote monitoring solutions will extend the continuum of care into patients’ homes, reducing readmission rates and optimizing resource utilization. Cultivating strategic alliances with regional stakeholders-government bodies, academic institutions, and patient advocacy groups-can unlock new reimbursement frameworks and awareness campaigns. By aligning R&D priorities with real-world clinical needs and payer expectations, industry leaders can accelerate time to market and secure sustainable competitive advantage.

Rigorous Research Foundations Driving Unbiased Market Insights

This report synthesizes data drawn from a rigorous blend of primary and secondary research methodologies. Primary research entailed in-depth interviews with key opinion leaders, including hepatologists, neurologists, and critical care specialists, as well as consultations with regulatory and reimbursement experts. Secondary sources encompassed peer-reviewed journals, published clinical trial outcomes, trade association reports, and proprietary databases tracking device approvals and pharmaceutical pipelines.

Our analytical framework integrates a bottom-up approach to map treatment adoption patterns alongside a top-down evaluation of regulatory and tariff policy impacts. Data triangulation ensures consistency between quantitative market indicators and qualitative insights, yielding a robust, multi-dimensional perspective. Throughout the research process, methodological rigor was maintained by adhering to industry best practices and validating findings through cross-referencing with independent expert advisory panels.

Consolidated Insights to Guide Future Growth Trajectories

In summary, the encephalopathy market stands at a critical inflection point where scientific breakthroughs, policy shifts, and strategic collaborations converge to reshape therapeutic paradigms. Stakeholders face both challenges and opportunities: rising tariffs necessitate agile supply chain solutions, while advancements in microbiome-based therapies pave the way for differentiated product offerings. Regional disparities underscore the need for flexible commercialization strategies that respect local market dynamics.

By thoughtfully leveraging segmentation insights-from device modalities to patient age groups-and aligning organizational priorities with emerging reimbursement models, companies can navigate complexities and capture growth. The recommendations and analysis presented herein equip industry participants with the strategic compass required to transform data into decisive action and, ultimately, to improve patient outcomes across a diverse global landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Devices
      • Blood Purification Systems
      • Hemodialysis Devices
      • Liver Support Devices
    • Pharmaceuticals
      • Lactulose
      • Rifaximin
    • Surgical Procedures
      • Liver Transplantation
      • Shunt Surgeries
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User
    • Home Care Settings
    • Hospitals
    • Specialty Clinics
  • Patient Age Group
    • Adult
    • Geriatric
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Salix Pharmaceuticals, Inc.
  • Abbott Laboratories
  • Fresenius Kabi AG
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Lupin Limited
  • Apotex Inc.
  • Sun Pharmaceutical Industries Ltd.
  • B. Braun Melsungen AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Encephalopathy Market, by Treatment Type
8.1. Introduction
8.2. Devices
8.2.1. Blood Purification Systems
8.2.2. Hemodialysis Devices
8.2.3. Liver Support Devices
8.3. Pharmaceuticals
8.3.1. Lactulose
8.3.2. Rifaximin
8.4. Surgical Procedures
8.4.1. Liver Transplantation
8.4.2. Shunt Surgeries
9. Encephalopathy Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Encephalopathy Market, by End User
10.1. Introduction
10.2. Home Care Settings
10.3. Hospitals
10.4. Specialty Clinics
11. Encephalopathy Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Americas Encephalopathy Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Encephalopathy Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Encephalopathy Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Salix Pharmaceuticals, Inc.
15.3.2. Abbott Laboratories
15.3.3. Fresenius Kabi AG
15.3.4. Sandoz International GmbH
15.3.5. Teva Pharmaceutical Industries Ltd.
15.3.6. Cipla Limited
15.3.7. Lupin Limited
15.3.8. Apotex Inc.
15.3.9. Sun Pharmaceutical Industries Ltd.
15.3.10. B. Braun Melsungen AG
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ENCEPHALOPATHY MARKET MULTI-CURRENCY
FIGURE 2. ENCEPHALOPATHY MARKET MULTI-LANGUAGE
FIGURE 3. ENCEPHALOPATHY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ENCEPHALOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ENCEPHALOPATHY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ENCEPHALOPATHY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ENCEPHALOPATHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ENCEPHALOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY BLOOD PURIFICATION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HEMODIALYSIS DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LIVER SUPPORT DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LACTULOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RIFAXIMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SHUNT SURGERIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. CANADA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 49. CANADA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 50. CANADA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 51. CANADA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 52. CANADA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. CANADA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. CANADA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. MEXICO ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 57. MEXICO ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 58. MEXICO ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 59. MEXICO ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. MEXICO ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. MEXICO ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. GERMANY ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. GERMANY ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 93. GERMANY ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 94. GERMANY ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 95. GERMANY ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. GERMANY ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. GERMANY ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 98. FRANCE ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 99. FRANCE ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 100. FRANCE ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 101. FRANCE ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 102. FRANCE ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. FRANCE ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. FRANCE ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. ITALY ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 113. ITALY ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 114. ITALY ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 115. ITALY ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 116. ITALY ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. ITALY ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. ITALY ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 119. SPAIN ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. SPAIN ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 121. SPAIN ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 122. SPAIN ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 123. SPAIN ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. SPAIN ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. SPAIN ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. DENMARK ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. DENMARK ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 149. DENMARK ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 150. DENMARK ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 151. DENMARK ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. DENMARK ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. DENMARK ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. QATAR ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 162. QATAR ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 163. QATAR ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 164. QATAR ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 165. QATAR ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. QATAR ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. QATAR ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. FINLAND ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. FINLAND ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 170. FINLAND ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 171. FINLAND ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 172. FINLAND ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. FINLAND ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. FINLAND ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. EGYPT ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. EGYPT ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 191. EGYPT ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 192. EGYPT ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 193. EGYPT ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. EGYPT ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. EGYPT ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. TURKEY ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. TURKEY ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 198. TURKEY ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 199. TURKEY ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 200. TURKEY ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. TURKEY ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. TURKEY ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 210. NORWAY ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 211. NORWAY ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 212. NORWAY ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 213. NORWAY ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 214. NORWAY ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. NORWAY ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. NORWAY ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 217. POLAND ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. POLAND ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 219. POLAND ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 220. POLAND ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 221. POLAND ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. POLAND ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. POLAND ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 239. CHINA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 240. CHINA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 241. CHINA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 242. CHINA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 243. CHINA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. CHINA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. CHINA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. INDIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 247. INDIA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 248. INDIA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 249. INDIA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 250. INDIA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. INDIA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. INDIA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. JAPAN ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. JAPAN ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 255. JAPAN ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 256. JAPAN ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 257. JAPAN ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. JAPAN ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. JAPAN ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 281. THAILAND ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 282. THAILAND ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 283. THAILAND ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 284. THAILAND ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 285. THAILAND ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. THAILAND ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. THAILAND ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 302. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 303. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 309. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 310. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 311. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 312. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 313. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 314. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 315. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 316. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 317. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2030 (USD MILLION)
TABLE 318. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 319. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 320. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 323. ENCEPHALOPATHY MARKET SHARE, BY KEY PLAYER, 2024
TABLE 324. ENCEPHALOPATHY MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Encephalopathy market report include:
  • Salix Pharmaceuticals, Inc.
  • Abbott Laboratories
  • Fresenius Kabi AG
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Lupin Limited
  • Apotex Inc.
  • Sun Pharmaceutical Industries Ltd.
  • B. Braun Melsungen AG

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 209.06 Million
Forecasted Market Value ( USD ) by 2030 $ 281.7 Million
Compound Annual Growth Rate6.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Overt Hepatic Encephalopathy Market - Product Image

Overt Hepatic Encephalopathy Market

  • Report
  • 250 Pages
  • Global
From
Hepatic Encephalopathy (HE) Treatment - Global Strategic Business Report - Product Image

Hepatic Encephalopathy (HE) Treatment - Global Strategic Business Report

  • Report
  • 283 Pages
  • Global
From
Hepatic Encephalopathy Market Report 2025 - Product Image

Hepatic Encephalopathy Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Encephalopathy- Pipeline Insight, 2025 - Product Image

Encephalopathy- Pipeline Insight, 2025

  • Clinical Trials
  • 210 Pages
  • Global
From
Developmental and Epileptic Encephalopathies (DEE) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Developmental and Epileptic Encephalopathies (DEE) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 233 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.